Extended Data Fig. 3: Expression of trogocytosis (TROG) antigen on CAR19 + NK cells is associated with a reduction in CD19 expression on B cells and predicts for worse outcomes after CAR19/IL-15 NK-cell treatment.
(a) Comparison of normalized CD19-MFI expression on B cells in the PB of patients before and 14 days after CAR19/IL-15 NK cell therapy. The data are shown for TROGlow (n = 23 patients; left) and TROGhigh groups (n = 13 patients; right). (b and c) Kaplan-Meier curves showing (b) overall survival (OS) and (c) progression-free survival (PFS) for patients categorized as TROGlow (n = 23 patients) vs. TROGhigh (n = 13 patients); mo: months. Numbers above each line represent the number of patients at risk. Numbers in parentheses represent the probabilities of OS or PFS at a given time point. Trogocytosis data were not available for one patient. The shaded areas represent 95% confidence interval (CI) of survival probability. P-values were determined by two-tailed paired student t test in panel a, or by log-rank test in panels b and c.
